Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis

G. Barosi; R. P. Gale

doi:10.1038/leu.2014.312

Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis

G. Barosi, R. P. Gale

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	740
Number of pages	1
Journal	Leukemia
Volume	29
Issue number	3
DOIs	https://doi.org/10.1038/leu.2014.312
Publication status	Published - Mar 9 2015

ASJC Scopus subject areas

Hematology
Cancer Research
Anesthesiology and Pain Medicine
Medicine(all)

Access to Document

10.1038/leu.2014.312

Cite this

@article{061320bbe8af4e0cbd0659aea1c20980,

title = "Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis",

author = "G. Barosi and Gale, {R. P.}",

year = "2015",

month = mar,

day = "9",

doi = "10.1038/leu.2014.312",

language = "English",

volume = "29",

pages = "740",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Reply to Passamonti et al

T2 - Ruxolitinib and survival improvement in patients with myelofibrosis

AU - Barosi, G.

AU - Gale, R. P.

PY - 2015/3/9

Y1 - 2015/3/9

UR - http://www.scopus.com/inward/record.url?scp=84924598223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924598223&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.312

DO - 10.1038/leu.2014.312

M3 - Article

C2 - 25363668

AN - SCOPUS:84924598223

VL - 29

SP - 740

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -

Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this